Nektar Therapeutics Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Nektar Therapeutics (NKTR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $34.48 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-03-13
- Nektar Therapeutics share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-09-30 was $3.23, a 65.49% decline year-over-year.
- Nektar Therapeutics share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-06-30 was $2.47, a 74.74% decline year-over-year.
- Nektar Therapeutics share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-03-31 was $6.61, a 38.91% decline year-over-year.
- Nektar Therapeutics share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2021-09-30 was $9.36, a 19.59% decline year-over-year.
- Nektar Therapeutics share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $34.48, a 201.93% increase from fiscal 2024.
- Nektar Therapeutics share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $11.42, a 2986.49% increase from fiscal 2023.
- Nektar Therapeutics share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $0.37, a 88.36% decline from fiscal 2022.
- Nektar Therapeutics share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $3.18, a 60.59% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $34.48 10-K · filed 2026-03-13 | ||||
| 2024-12-31 | $11.42 10-K · filed 2026-03-13 | $0.76 10-K · filed 2025-03-14 | |||
| 2023-12-31 | $0.37 10-K · filed 2025-03-14 | ||||
| 2022-12-31 | $3.18 10-K · filed 2024-03-05 | ||||
| 2022-09-30 | $3.23 10-Q · filed 2022-11-04 | $3.24 10-Q · filed 2022-11-04 | |||
| 2022-06-30 | $2.47 10-Q · filed 2022-08-05 | $3.33 10-Q · filed 2022-08-05 | |||
| 2022-03-31 | $6.61 10-Q · filed 2022-05-06 | ||||
| 2021-12-31 | $8.07 10-K · filed 2024-03-05 | ||||
| 2021-09-30 | $9.36 10-Q · filed 2022-11-04 | $9.72 10-Q · filed 2022-11-04 | |||
| 2021-06-30 | $9.78 10-Q · filed 2022-08-05 | $10.23 10-Q · filed 2022-08-05 | |||
| 2021-03-31 | $10.82 10-Q · filed 2022-05-06 | ||||
| 2020-12-31 | $10.70 10-K · filed 2023-02-28 | ||||
| 2020-09-30 | $11.64 10-Q · filed 2021-11-05 | $11.68 10-Q · filed 2021-11-05 | |||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-06 | $11.88 10-Q · filed 2021-08-06 | |||
| 2020-03-31 | $11.88 10-Q · filed 2021-05-07 | ||||
| 2019-12-31 | $12.25 10-K · filed 2022-03-01 | ||||
| 2018-12-31 | $29.86 10-K · filed 2021-02-26 | ||||
| 2017-12-31 | $20.08 10-K · filed 2020-02-28 | ||||
| 2011-09-30 | $2.79 10-Q · filed 2011-11-04 | $5.30 10-Q · filed 2011-11-04 | |||
| 2011-06-30 | $4.90 10-Q · filed 2011-08-05 | $5.65 10-Q · filed 2011-08-05 | |||
| 2010-09-30 | $6.75 10-Q · filed 2011-11-04 | $6.24 10-Q · filed 2011-11-04 | |||
| 2010-06-30 | $7.34 10-Q · filed 2011-08-05 | $6.17 10-Q · filed 2011-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |